

CURRENT REPORT 31/2021

September 24, 2021

Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center

The Management Board of Ryvu Therapeutics S.A. ("Company") hereby informs, that on September 24, 2021 the Company has filed with the District Court in Kraków, IX Commercial Division, ul. Przy Rondzie 7, a lawsuit against Mota-Engil Central Europe S.A. with its seat in Kraków ("Contractor") for the payment of PLN 13,756,717.07. With this lawsuit, the Company seeks claims related to the agreement for "Construction of the Research and Development Center of Innovative Drugs Selvita S.A." ("Contract"), the conclusion of which was announced by the Company in the current report No. 27/2018 of August 13, 2018.

The total value of the Contract was PLN 68,783,585.34 including VAT. The Contractor supposed to complete the Contract within 15 months after the execution of the Contract, which has not been done. The Parties have extended Time for Completion of the Contract until April 30, 2020 (by way of concluding two annexes) and modified the scope of works to be performed under the Contract, including exclusion of the part of the works and performance of the substitution works.

Company seeks contractual penalties from the Contractor in the above-mentioned amount along with statutory interest for delay, which includes claiming the payment of contractual penalties for exceeding the Time for Completion by 78 days comparing to the extended time for completion agreed in the annexes and exceeding the milestones indicated in the works schedule and for failure to remove or improper removal of defects and faults indicated in the building take-over certificate and under the warranty for defects.

Legal basis: Article 17.1 of the Market Abuse Regulation

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Tomasz Nocuń – Proxy

